Uptake of new drugs in the early post-approval period in the Mini-Sentinel distributed database

Pharmacoepidemiology and Drug Safety

Volumn 25, Issue 9, 2016, Pages 1023-1032

  Mott, Katrina ^a,b   Graham, David J ^a   Toh, Sengwee ^c   Gagne, Joshua J ^d   Levenson, Mark ^a   Ma, Yong ^a   Reichman, Marsha E ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

active surveillance; distributed databases; drug safety; new molecular entities; pharmacoepidemiology; Sentinel

Indexed keywords

CARGLUMIC ACID; DABIGATRAN; DESVENLAFAXINE; NEW DRUG; PRASUGREL; ROFLUMILAST; TETRABENAZINE; VILAZODONE;

ADULT; ARTICLE; DATA BASE; DRUG SAFETY; DRUG UTILIZATION; FEMALE; HUMAN; INCIDENCE; MALE; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 84984908086     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.4013     Document Type: Article

References (28)

1. Behrman RE, Benner JSH, Brown JS, et al. Developing the Sentinel System: a national resource for evidence development. N Engl J Med 2011; 364: 498–499.
2. Platt R, Carnahan R. The U.S. Food and Drug Administration's Mini-Sentinel Program. Pharmacoepidemiol Drug Saf 2012; 21: 1–303.
3. Food and Drug Administration. The Sentinel Initiative: National Strategy for Monitoring Medical Product Safety. Food and Drug Administration: Silver Spring, MD, 2008.
4. Curtis LH, Weiner MG, Boudreau DM, et al. Design considerations, architecture, and use of the Mini-Sentinel distributed data system. Pharmacoepidemiol Drug Saf 2012; 21: 23–31.
5. Toh S, Avorn J, D'Agostino RB, et al. Re-using Mini-Sentinel data following rapid assessments of potential safety signals via modular analytic programs. Pharmacoepidemiol Drug Saf 2013; 22: 1036–1045.
6. Robb MA, Racoosin JA, Sherman RE, et al. The US Food and Drug Administration's Sentinel Initiative: expanding the horizons of medical product safety. Pharmacoepidemiol Drug Saf 2012; 21(S1): 9–11.
7. Platt, R, Archdeacon P, Bell C, et al. Mini-sentinel methods, prospective routine observational monitoring program tools (PROMPT): users' guide. June 2014.
8. Southworth MR, Reichman M, Unger E. Dabigatran and postmarketing reports of bleeding. N Engl J Med 2013; 368: 1272–1274.
9. Butler M, Zhou E, Zhang F, et al. Mini-sentinel regulatory assessment: report of the impact of the 2010 FDA regulatory actions on LABA medication use. Mini-sentinel.org: 2014.
10. Toh S, Reichman ME, Houstoun M, et al. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. Arch Intern Med 2012; 172: 1582–1589.
11. Gerhard T, Raebel M, Reichman ME, et al. Mini-sentinel assessment: metabolic effects of second generation antipsychotics in youth. Mini-sentinel.org. 2014.
12. New drugs at FDA: CDER's new molecular entities and new therapeutic biological products.http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/default.htm
13. Mini-sentinel modular programs: modular program 8: uptake, use and persistence of new molecular entities (NMEs). 2014. Mini-sentinel.org. http://www.mini-sentinel.org/work_products/Data_Activities/Mini-Sentinel-Modular_Program_8-Documentation.pdf
14. Shiue WK, Bain LJ. Experiment size and power comparisons for two-sample Poisson tests. Appl Stat 1982; 31: 130–134.
15. Koton S, Schneider AC, Rosamond WD, et al. Stroke incidence and mortality trends in US communities, 1987 to 2011. JAMA 2014; 312(3): 259–268.
16. Yeh RW, Sidney S, Chandra M, Sorel M, Selby JV, Go AS. Population trends in the incidence and outcomes of acute myocardial infarction. N Eng J Med 2010; 362: 2155–2165.
17. Gagne JJ, Rassen JA, Choudhry NK, et al. Near-real-time monitoring of new drugs: an application comparing prasugrel versus clopidogrel. Drug Saf 2014; 37: 151–161.
18. Avorn JA. The promise of pharmacoepidemiology in helping clinicians assess drug risk. Circulation 2013; 128: 745–748.
19. Maro JC, Brown JS. Impact of exposure accrual on sequential postmarket evaluations: a simulation study. Pharmacoepidemiol Drug Saf 2011; 20: 1184–1191.
20. Loke YK, Kwok CS, Singh S. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. Br Med J 2011; 342: d1309.
21. Graham DJ, Oullett-Helstrom R, MaCurdy TE, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010; 304: 411–408.
22. Wertz DA, Chang CL, Sarawate CA, et al. Risk of cardiovascular events and all-cause mortality in patients treated with tiazolidinediones in a managed-care populations. Circ Cardiovasc Qual Outcomes 2010; 3: 538–45.
23. Brownstein JS, Murphy SN, Golfine AB, et al. Rapid identification of myocardial infarction risk associated with diabetes medications using electronic medical records. Diabetes Care 2010; 33: 526–31.
24. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005; 365: 475–481.
25. Johnsen JP, Larsson H, Tarone RE, et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs. Arch Intern Med 2005; 165: 978–984.
26. Ray WA, Varas-Lorenzo C, Chung CP, et al. Cardiovascular risks of nonsteroidal anti-inflammatory drugs in patients after hospitalization for serious coronary heart disease. Circ Cardiovasc Qual Outcomes 2009; 2: 155–163.
27. Solomon DH, Schneeweiss S, Glynn RJ, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004; 109: 2068–2073.
28. Yih W, Kulldorff M, Sandhu S, et al. Prospective influenza vaccine safety surveillance using fresh data in the Sentinel System. Pharmacoepidemiol Drug Saf 2016; 25: 481–492.